Jonathan Zalevsky
2020
In 2020, Jonathan Zalevsky earned a total compensation of $4.9M as Chief Research and Development Officer at Nektar Therapeutics, a 32% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $500,000 |
|---|---|
| Option Awards | $1,501,672 |
| Salary | $683,000 |
| Stock Awards | $2,247,676 |
| Other | $9,149 |
| Total | $4,941,497 |
Zalevsky received $2.2M in stock awards, accounting for 45% of the total pay in 2020.
Zalevsky also received $500K in non-equity incentive plan, $1.5M in option awards, $683K in salary and $9.1K in other compensation.
Rankings
In 2020, Jonathan Zalevsky's compensation ranked 2,247th out of 13,090 executives tracked by ExecPay. In other words, Zalevsky earned more than 82.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,247 out of 13,090 | 83rd |
Division Manufacturing | 862 out of 5,621 | 85th |
Major group Chemicals And Allied Products | 308 out of 2,254 | 86th |
Industry group Drugs | 262 out of 1,954 | 87th |
Industry Pharmaceutical Preparations | 187 out of 1,459 | 87th |
Source: SEC filing on April 30, 2021.
Zalevsky's colleagues
We found four more compensation records of executives who worked with Jonathan Zalevsky at Nektar Therapeutics in 2020.